However, clinical trials studying new drugs or therapeutic regimens for asthma generally exclude smokers [8, 12]. More recently, this concern was also extended to former smokers [13–15]. The rationale for such exclusion is that tobacco use by asthma patients is associated with numer- ous adverse outcomes, making it difficult to analyze the real effectiveness of the drug being tested [16].
.